Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering
Aptorum Group (NASDAQ: APM) priced a registered direct offering of 1,000,000 Class A ordinary shares at $2.00 per share for expected gross proceeds of $2.0 million, with a concurrent private placement of unregistered warrants to buy up to 2,000,000 shares at $2.00 per share. Closing is expected on or about October 14, 2025, subject to customary conditions.
The warrants are exercisable upon issuance, expire 24 months after effectiveness of a resale registration statement, and could provide up to $4.0 million additional gross proceeds if fully exercised. Net proceeds are intended to fund expenses tied to the planned merger with DiamiR Biosciences and general working capital; the merger remains subject to contingencies including shareholder approval.
Aptorum Group (NASDAQ: APM) ha annunciato un'offerta diretta registrata di 1.000.000 azioni ordinarie di Classe A a 2,00 $ per azione, con proventi lordi attesi di 2,0 milioni di dollari, insieme a un collocamento privato concomitante di warrant non registrati per l'acquisto di fino a 2.000.000 azioni a 2,00 $ per azione. La chiusura è prevista indicativamente per 14 ottobre 2025, soggetta a condizioni consuete.
I warrant sono esercitabili al momento dell'emissione, scadono 24 mesi dopo l'eleggibilità di una dichiarazione di registrazione per la rivendita e potrebbero fornire ulteriori proventi lordi fino a 4,0 milioni di dollari se esercitati per intero. I proventi netti sono destinati a finanziare le spese legate alla prevista fusione con DiamiR Biosciences e al capitale circolante generale; la fusione resta soggetta a contingencies tra cui l'approvazione degli azionisti.
Grupo Aptorum (NASDAQ: APM) fijó una oferta directa registrada de 1.000.000 de acciones ordinarias Clase A a 2,00 USD por acción para ingresos brutos esperados de 2,0 millones de USD, con una colocación privada concurrente de warrants no registrados para comprar hasta 2.000.000 de acciones a 2,00 USD por acción. El cierre se espera aproximadamente para el 14 de octubre de 2025, sujeto a condiciones habituales.
Los warrants son exercibles al momento de la emisión, expiran 24 meses después de la eficacia de una declaración de registro para reventa, y podrían generar hasta 4,0 millones de USD adicionales si se ejercen en su totalidad. Los ingresos netos se destinarán a financiar gastos vinculados a la fusión prevista con DiamiR Biosciences y al capital de trabajo general; la fusión sigue sujeta a contingencias, incluida la aprobación de los accionistas.
Aptorum Group (NASDAQ: APM) 은 주당 2.00 달러에 1,000,000주 Class A 보통주를 등록된 직접 공모로 가격 책정했고, 예상 총수익은 200만 달러입니다. 동시에 등록되지 않은 워런트를 비등록 비공개 배치로 발행하여 최대 2,000,000주를 2.00달러에 매수할 수 있습니다. 종결은 약 2025년 10월 14일경으로 예상되며 관례적 조건을 전제로 합니다.
워런트는 발행 시 행사 가능하며, 재판매 등록서의 효력이 발효된 후 24개월 동안 만료되고, 전량 행사될 경우 추가로 최대 400만 달러의 총수익을 제공할 수 있습니다. 순수익은 DiamiR Biosciences와의 예정된 합병에 따른 비용 및 일반 운영 자본 조달에 사용될 예정이며, 합병은 주주 승인 등 contingencies가 남아 있습니다.
Aptorum Group (NASDAQ : APM) a fixé une offre directe enregistrée de 1 000 000 d'actions ordinaires de classe A à 2,00 $ par action pour des produits bruts attendus de 2,0 millions de dollars, avec une mise en place privée concomitante de warrants non enregistrés permettant d'acheter jusqu'a 2 000 000 d'actions à 2,00 $ par action. La clôture est prévue vers le 14 octobre 2025, sous réserve des conditions habituelles.
Les warrants sont exerçables à l'émission, expirent 24 mois après l'efficacité d'une déclaration d'enregistrement en vue de la revente, et pourraient générer jusqu'à 4,0 millions de dollars supplémentaires de produits bruts si tous sont exercés. Le produit net est destiné à financer les dépenses liées à la fusion envisagée avec DiamiR Biosciences et au fonds de roulement général; la fusion demeure soumise à des contingences y compris l'approbation des actionnaires.
Aptorum Group (NASDAQ: APM) hat ein registriertes Direct-Offering von 1.000.000 Class-A-Aktien zu je 2,00 $ pro Aktie mit voraussichtlichen Bruttoerlösen von 2,0 Mio. $ festgelegt, verbunden mit einer gleichzeitigen privaten Platzierung von nicht registrierten Warrants zum Kauf von bis zu 2.000.000 Aktien zu 2,00 $ pro Aktie. Der Abschluss wird voraussichtlich am oder um den 14. Oktober 2025 erfolgen, vorbehaltlich üblicher Bedingungen.
Die Warrants sind bei Ausgabe ausübbar, laufen 24 Monate nach Inkrafttreten einer Wiederverkaufsregistrierungsbescheinigung und könnten, wenn sie vollständig ausgeübt werden, zusätzliche Bruttoerlöse von bis zu 4,0 Mio. $ bringen. Die Nettomittel sollen zur Finanzierung von Kosten im Zusammenhang mit der geplanten Fusion mit DiamiR Biosciences und allgemeinem Working Capital verwendet werden; die Fusion bleibt unter Vorbehalt von Kontingenzen, einschließlich der Zustimmung der Aktionäre.
مجموعة Aptorum (ناسداك: APM) حدّدت عرضاً مباشراً مسجلاً لبيع 1,000,000 سهم عادي من الفئة A بسعر 2.00 دولار للسهم، بإيرادات إجمالية متوقعة تبلغ 2.0 مليون دولار، مع طرح خاص متزامن لــ
يمكن ممارسة الــ warrants عند الإصدار، وتنتهي صلاحيتها بعد 24 شهراً من تاريخ فعالية بيان تسجيل لإعادة البيع، وقد توفر نحو 4.0 ملايين دولار إضافية من الإيرادات الإجمالية إذا تم ممارستها بالكامل. تستخدم العوائد الصافية لتمويل النفقات المرتبطة بالاندماج المخطط مع DiamiR Biosciences ورأس المال العامل العام؛ يظل الدمج خاضعاً لظروف تشمل موافقة المساهمين.
Aptorum Group(纳斯达克股票代码:APM) 定价了一项注册直接要约,发行1,000,000 股 A 类普通股,发行价为每股 2.00 美元,预计毛收益为 200 万美元,同时进行未注册认股权证的并行私募发行,可购买最多 2,000,000 股,价格同为每股 2.00 美元。预计在 2025 年 10 月 14 日左右完成,需符合惯常条件。
认股权证自发行时可行使,自再销售注册声明生效之日起 24 个月到期,如果全部行使,可能再提供最高 400 万美元的额外毛收益。净收益拟用于资助与拟议的与 DiamiR Biosciences 的并购相关的费用及一般运营资金;并购仍受包括股东批准在内的或有条件限制。
- Immediate gross proceeds of $2.0 million
- Upside: potential additional gross proceeds of $4.0 million from warrants
- Proceeds earmarked to fund merger expenses and working capital
- Potential issuance of up to 3,000,000 shares causing shareholder dilution
- No assurance warrants will be exercised for cash or at all
- Closing subject to customary conditions; merger contingent on shareholder approval
- Placement agent fees and offering expenses will reduce net proceeds
Insights
Small registered direct raise of
The company will issue 1,000,000 Class A ordinary shares at
Key dependencies and risks include the anticipated closing around
Concrete items to watch: confirmation of closing on or about
NEW YORK, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000 Class A ordinary shares at a purchase price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be
The ordinary shares (but not the unregistered warrants and the ordinary shares underlying the unregistered warrants) described above are being offered by the Company pursuant to a “shelf” registration statement on Form F-3 (File No. 333-268873) that was declared effective by the Securities and Exchange Commission (the “SEC”) on January 19, 2023. The offering of the ordinary shares is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
The unregistered warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the ordinary shares underlying such unregistered warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the unregistered warrants and underlying ordinary shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. For more information, please visit the company’s website at www.aptorumgroup.com.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the exercise of the unregistered warrants prior to their expiration and the intended use of proceeds from the offering, as well as statements regarding the consummation and closing of the proposed merger between Aptorum Group and DiamiR Biosciences Corp. (the “Merger”), the satisfactory completion of all conditions to the Merger, the shareholder’s approval necessary for the issuance of shares in the Merger and re-domestication of Aptorum Group, the parties ability to successfully operate its business and provide value to stockholders after completion of the Merger, Aptorum Group and and DiamiR’s future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing, future or ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Aptorum Group’s and DiamiR’s industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for increasing revenue and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which the Company operates, customer demand, the financial markets, economic, business and regulatory and other factors, such as the Company’s ability to execute on its strategy. More detailed information about risk factors can be found in the Company’s Annual Report on Form 20-F and the Company’s Registration Statement on Form S-4 filed with the SEC on October 6, 2025, under the heading “Risk Factors,” and in other reports filed by the Company, including reports on Form 6-K. The Company does not undertake any duty to update forward-looking statements after the date of this press release, except as required by law.
Contact:
Aptorum Group Limited
Investor Relations Department
investor.relations@aptorumgroup.com
+44 20 80929299
